• Histological or cytological confirmation of NSCLC.

‣ Part A

• Clinical Stage II-IIIB (N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible.

∙ Pathologic Stage II-IIIB (N2) NSCLC treated with initial upfront resection.

⁃ Part B - Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy.

• Must have disease with evidence of KRAS G12C mutation.

• Must have known programmed death-ligand 1 (PD-L1) expression

• Must have an ECOG performance status of 0 or 1.

• Able to swallow oral medication.

• Must have adequate laboratory parameters.

• Contraceptive use should be consistent with local regulations for those participating in clinical studies.

• Women of childbearing potential must

‣ Have a negative pregnancy test.

⁃ Not be breastfeeding during treatment